Philadelphia, Pennsylvania--(Newsfile Corp. - June 26, 2023) - A federal securities fraud class action complaint has been filed against Charles River Laboratories International, Inc. (NYSE: CRL).
The lawsuit alleges Charles River, via certain of its officers and directors, made materially false and/or misleading statements and/or failed to disclose material adverse facts about the Company's business, operations, and prospects, including: (1) that Charles River had engaged in illegal activity with respect to its importation of primates for research; (2) that, as a result, Charles River was at a heightened risk of criminal and regulatory investigation by the U.S. Department of Justice; (3) that, as a result, Charles River would be forced to suspend shipments of primates from Cambodia; and (4) that, as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis when made.
Current Charles River shareholders who have continuously held Charles River shares since on or before May 5, 2020, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them.
If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/charles-river-shareholder-investigation/, contact us at jgrabar@grabarlaw.com, or call Joshua Grabar at 267-507-6085.
Attorney Advertising Disclaimer
Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: jgrabar@grabarlaw.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/171426
